India Generics Makers Face Added Delay In U.S. Exclusivity Applications
This article was originally published in PharmAsia News
Executive Summary
India's makers of generic drugs, including Aurobindo, Dr. Reddy's Laboratories, Lupin and Ranbaxy Laboratories, face a slowdown in U.S. approval of filings for six-month exclusivity.